Dopamine D3 Receptor Partial Agonists and Antagonists as Potential Drug Abuse Therapeutic Agents

ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTDopamine D3 Receptor Partial Agonists and Antagonists as Potential Drug Abuse Therapeutic AgentsAmy Hauck Newman, Peter Grundt, and Michael A. NaderView Author Information Medicinal Chemistry Section, National Institute on Drug AbuseIntramural Research Program, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, Maryland 21224, and Departments of Physiology/Pharmacology & Radiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1083 Cite this: J. Med. Chem. 2005, 48, 11, 3663–3679Publication Date (Web):April 21, 2005Publication History Received26 October 2004Published online21 April 2005Published inissue 1 June 2005https://pubs.acs.org/doi/10.1021/jm040190ehttps://doi.org/10.1021/jm040190ereview-articleACS PublicationsCopyright © 2005 American Chemical SocietyRequest reuse permissionsArticle Views1940Altmetric-Citations164LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Amines,Antagonists,Pharmaceuticals,Receptors,Selectivity Get e-Alerts